Your SlideShare is downloading. ×
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Federico Villamil - Argentina - Tuesday 29 - Graft and Patient Outcomes

378

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
378
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Reasons may be prevalence related, but may be impacted on disease term availablility in SRTR data.
  • Transcript

    • 1. 2011 Organ Donation Congress Buenos Aires, November 27-30, 2011 Graft and Patient Outcomes Challenges in Liver Transplantation Federico G. Villamil Liver Transplantation Unit Buenos Aires British Hospital
    • 2. Priorities in Liver Transplantation The Past
      • Acute and chronic rejection
      • Infectious complications
      Survival Prophylaxis Therapy
      • 90% at 1 yr
      • 80% at 5 yrs
      10-20% 2-3%
    • 3.
      • Increase the number of donors and optimize organ allocation
      • Minimize long-term adverse effects of immunosuppressive agents
      • Prevent or effectively treat recurrent disease
      The Present Priorities in Liver Transplantation
    • 4. 1980 1990 CsA Tac MMF 1960 Steroids AZA Steroids Steroids AZA Tac: 88.8% , CsA 5.7% Tac + MMF + Steroids: 54.7% SRTR Annual Report 2009 (n=5826) ATG, Anti-IL2, Campath, Rituximab Sirolimus, everolimus Belatacept, sotrastaurin 2011 At present CNI-free IS in liver transplantation is the exception rather than the rule  Minimization
      • Nephrotoxicity
      • Hypertension
      • Hyperlipidemia
      • Neurotoxicty
      • Diabetes mellitus
      ¿Calcineurin-free immunosupression?
    • 5. Challenges in Liver Transplantation Hepatitis B
    • 6. OLT for Hepatitis B : “A happy story” HBV Recurrence 1980’s No inmunoprofilaxis 80-90% HBIg monotherapy 20-30% HBIg + LAM 5-10% HBIg + ADV (  LAM) 2-5% HBIg +ETV o TDF ?? From an absolute contraindication to a universally accepted indication 1990 2000 2005 2010 HBIg-free prophylaxis?
    • 7. Challenges in Liver Transplantation Hepatitis C
    • 8. Accelerated fibrogenesis (30% cirrhosis at 5 years) Natural History of Recurrent Hepatitis C Decreased patient and graft survival Strategies for Management of Patients with HCV Recurrence
      • Identify reliable predictors of severe HCV recurrence (fibrosis) to minimize their impact on allograft disease
    • 9. Effect of Donor Age on Severity of HCV Recurrence Following OLT Berenguer et al (2002) % HCV-related graft cirrhosis Donor Age
    • 10. Is CsA antiviral in vivo? Are mTor inhibitors anti-fibrogenic? Immunosuppression in Hepatitis C Changes in immunosuppresion over time should be slow and gentle  Avoid intense imunosuppression followed by rapid withdrawal For mild episodes of rejection intensification of baseline immunosuppression should be attempted before administering steroid boluses
    • 11. The HCV- Diabetes -Kidney Connection HCV Diabetes (IR) Renal failure HCV is an Independent predictor of renal failure and may accelerate the progression of diabetic nephropathy HCV increases the risk of DM Diabetes (IR) increases the severity of HCV
    • 12. Accelerated fibrogenesis (30% cirrhosis at 5 years) Natural History of Recurrent Hepatitis C Decreased patient and graft survival Strategies for Management of Patients with HCV Recurrence
      • Identify reliable predictors of severe HCV recurrence (fibrosis) to minimize their impact on allograft disease
      • Antiviral therapy
    • 13. Histological Outcome of Patients With SVR Post-OLT Inflammation Fibrosis %
    • 14. Antiviral Therapy Improves Long-Term Outcome of HCV Recurrence * Significant differences SVR NR Treated Untreated 100%* 93%* NA 43% 69% NA NA 74%* 92.5%* NA 30 Kornberg (08) 62% 89 Berenguer (08) 66% 165 Veldt (08) Patient Survival (5-7 Years) N Author
    • 15. Efficacy of PEG-Ribavirin Therapy for HCV Recurrence 25 reported studies including 835 patients 8% 55% SVR (all genotypes): 259/835 (31%)
    • 16. There is an urgent need for more safe and effective antiviral agents SVR in Naive Genotype 1 Patients Triple therapy Triple therapy Telaprevir Boceprevir %
    • 17. Garg V et al. Hepatology 2011 AUC increase x 70 Tacrolimus + telaprevir Tacrolimus Impact of Telaprevir on CNI Exposure
    • 18. Hepatocellular Carcinoma Challenges in Liver Transplantation
    • 19. Liver Transplantation for HCC Mazzaferro V y col (1996) Imaging studies with a single nodule <5 cm or up to 3 nodules <3 cm Recurrence-free survival 90% 86% 83% 83% HCC recurrence: 8% % “ Milan Criteria”
    • 20. Recommendations for OLT for HCC International Consensus Conference Clavien PA et al (2011)
      • Milan criteria are currently the benchmark for the selection of HCC patients for OLT
      • In patients following LDLT outside the accepted criteria for DDLT, re-OLT for graft failure using a deceased donor organ is not recommended
      Are the Milan Criteria too restrictive?
    • 21. Is tumor biology the answer? Can we safely go beyond Milan Criteria?
    • 22. Results of OLT in HCC and non-HCC Patients According to Immunosuppression Toso C et al NS 78% 79% NS 70% 68% MMF <0.001 79% 73% NS 69% 69% CsA <0.001 73% 79% NS 68% 70% Tac NS 78% 79% <0.01 68% 74% Anti-CD25 NS 79% 74% <0.05 69% 83% Sirolimus p No Yes p No Yes No HCC (n=12167) HCC (n=2491) 5-Year Survival Droga “ Anti-cáncer agent”
    • 23. 5-Year survival Toso C et al (2010) Results of OLT in HCC Patients According to Immunosuppression Multivariate Analysis (HCC patients) Sirolimus: HR 0.53 (0.31-0.92) p<0.05 Anti-CD25: HR 0.64 (0.45-0.9) p<0.01
    • 24. Secondary Objectives SILVER Study (RCT) Primary Objective
      • Patient survival
      • Time-to-recurrence
      • Tumor progression
      • Renal function
      • De novo malignancies
      Recurrence-free survival
    • 25. Challenges in Liver Transplantation NASH
    • 26. Metabolic Syndrome and Liver Transplantation Metabolic syndrome in up to 60% of post-transplant patients 30-40% 20-75% DM or IGT 60-70% 67% Hypertension 50-70% 12-85% Elevated lipids OLT NAFLD
    • 27. Present and Future Demand for Liver Transplantation for NASH % of LT Charlton MR, Clin Gastro & Hep 3:2005.
    • 28.  
    • 29.
      • Most likely, ETV and TDV will replace LAM and ADV both pre- and post-OLT
      • In the era of antivirals high dose IV HBIg regimens are no longer necessary:
        • Low doses
        • IM or SC
        • Finite course in low-risk patients
      • HBIg-free prophylaxis?
      Prophylaxis of HBV Recurrence
    • 30. Actuarial Rates of Fibrosis in Patients with HCV Recurrence Fundación Favaloro 1995-2007 72 consecutive HCV+ patients with mean follow-up of 69 months and 5  2 protocol biopsies 97% 81% 49% 21% F1 F2 F3 F4
    • 31. HCV Infection is Associated with Decreased Post-OLT Survival HCV-Neg (n=6597) HCV-Pos (n=4439) 81.8% 76.6% 77.8 69.9 p<0.0001 HCV recurrence is the major cause of graft loss and death Forman L et al (2002)
    • 32. Strategies for Management of Patients with HCV Recurrence
      • Identification of reliable predictors of severe recurrence to minimize their impact on allograft disease
    • 33. Tumor Size is a Surrogate Marker for Histological Predictorsof Recurrence Figueras J et al (2001) Tumor diameter of main nodule (n=305) %

    ×